Canaccord downgraded Quanterix (QTRX) to Hold from Buy with a price target of $5, down from $12. following the Q2 miss. The firm cites a lack of near-term visibility and catalysts to move the shares higher for the downgrade. Quanterix’s results were impacted by increasing headwinds in biopharma and continued National Institutes of Health funding uncertainty, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix’s Strategic Acquisition and Growth Potential Amidst Challenges
- Quanterix Reports Q2 2025 Financial Results
- Quanterix Hold Rating: Balancing Underperformance with Strategic Opportunities
- Quanterix Adopts New Bylaws Amid Financial Challenges
- Quanterix Announces Cooperation Agreement with Kent Lake